Pharmaceuticals & Biotech Canadian Community

Cybin’s aggressive analyst price targets make sense when you view the company through a true late-stage biotech lens rather than a speculative psychedelic stock. With more than US$225 million in cash after retiring all debt, Cybin is now one of the only fully funded companies in the entire sector with enough runway to complete multiple Phase 3 trials and deliver two major clinical readouts—Phase 2 CYB004 data in Q1 2026 and pivotal Phase 3 CYB003 results in Q4 2026.Read more

BioNxt is developing two platform technologies: a sublingual thin-film technology (ODF) for smart drug delivery and a novel chemotherapy platform in which the active ingredient is activated directly in the tumor—targeting and killing cancer cells while sparing healthy cells. The ODF technology is protected by a European broad patent (intention-to-grant, May 2025), covering a wide range of sublingual active ingredients and is being nationalized in key markets.Read more

Organigram Holdings Inc. has seen some significant developments in the past four months: ✓ Acquisition of Motif Labs: In December 2024, Organigram acquired Motif Labs, a Canadian cannabis company, for C$90 million upfront.Read more

Cybin is pushing a psychedelic-based depression treatment that may work with only one or two sessions, which could make it easier to use than some existing options. Fast-track attention from U.S. regulators and upcoming trial results in depression and anxiety could be the next big make-or-break moments.Read more

Aurora Cannabis is leaning into overseas medical markets like Europe and Australia, where strict rules can keep weaker rivals out and support better profits. The big question is whether competition, rising costs, or sudden rule changes in key countries could derail that path.Read more

Curaleaf aims to ride the global shift toward medical cannabis and wellness, using new markets, branded products, and a health-focused inhalation device to stand out as more countries open up. But tougher pricing, shifting rules, and the need to fund expansion could make it harder to turn growth into lasting profits.Read more

A generic drug maker pushes into more complex medicines and a wave of new product launches, which could change where its growth comes from and how steady profits are. But the story hinges on winning early launch windows and keeping manufacturing and supply chains running smoothly as competition and policy pressures build.Read more

Auxly is leaning on the strength of its Back Forty brand and wider reach across Canadian cannabis shops to keep growing, even as the market stays highly competitive. The next big swing factor is whether its push to upgrade production quality and open doors for international shipments pays off—or turns into a costly bet.Read more

HLS Therapeutics is trying to grow its heart-health business in Canada, with new cholesterol medicines and wider insurance coverage that could boost sales without needing a much bigger cost base. The catch is that the story leans on a small handful of drugs and on Canadian approval and pricing decisions that could slow growth or squeeze profits.Read more